Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Go back to Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting| COGENT (NASDAQ: COGT) | Delayed: 35.84 +1.30 (3.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.54 | 52 Week High | $5.57 | |||
| Open | $35.34 | 52 Week Low | $2.90 | |||
| Day High | $36.03 | P/E | 162.91 | |||
| Day Low | $35.02 | EPS | $0.22 | |||
| Volume | 3,175,349 | |||||
